YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Stock Market Ends First Half Solidly As Nasdaq Leads All – $AAPL $ADT $AI $ATOS $INVO $LTRN $TSLA Rise!

By John F. Heerdink, Jr.


Quote of the Day:  “Science may never come up with a better office communication system than the coffee break.” – Earl Wilson


Happy Saturday!

I hope that you had a great week,  already enjoyed your first cup of Joe this morning, and that you have great plans ahead for your weekend.

As for the broad markets this week, stocks moved significantly higher over the course week and ended the first help 2023 well into the green. The S&P 500 closed at 4,450.38 (+2.3%) for the week and is now up 15.9% YTD as 11 out of the 11 sectors closed in the green this week with the real estate sector up 5%, the energy sector up 4.8%, the materials sector up 4%, the industrials up 3.9%, the financials up 2.9%, the information technology up 2.9%, & the consumer discretionary sector up 2.5% leading the way.

The Dow 30 closed at 34,407.60 (+2%) for the week and is now up 3.8% YTD.  The Walt Disney Company (DIS) closed at $89.28, +1.34% over the last 5-days. Nike (NKE) closed at $110.37, +.78% over the last 5-days despite missing quarterly expectations. 

The Nasdaq closed at 13,787.92 (+2.8%) and is now up an amazing 31.7% YTD.  The ‘Magnificent Seven’ performed as follows over the last 5-days: which includes Apple (AAPL, $193.97, +2.31% over the last 5-days, +49.29% YTD), Alphabet (GOOGL $119.70, -2.16% over the last 5-days +35.67%, GOOG, $120.97, -1.67%, +36.33% YTD), Microsoft (MSFT, $340.54, +1.65% over the last 5-days, +42% YTD), Amazon (AMZN, $130.36, +.80% over last 5-days, +55.19% YTD), Meta (META,$286.98, -.61%, +138.47% YTD), Tesla (TSLA, $261.77, +2.01% over last 5-days, +261.77, +112.51% YTD), and Nvidia (NVDA, $423.02, +.22% over the last 5-days, +189.46% YTD). This so-called group accounts for ~84% of the Nasdaq 100’s ~$4T growth in market cap YTD. Netflix (NFLX) also cooled off after its recent run to close at $440.49, +3.88% over the last 5-days, +49.38% YTD. C3 AI (NYSE: AI)  over the last 5-days closed at $36.43, +9.10% , & 225.56% YTD.

The small caps on the Russell 2000 closed at 1,888.73 (+3.7%) for the week & is now up 7.2% YTD. The MicroCaps also moved higher this week as the iShares Micro-Cap ETF (IWC) closed at $109.30,+1.60% this week & is now up 1.36% YTD.  

The macroeconomic schedule provided another group og interesting reports. On Tuesday, the Total durable goods orders repot that came in 1.7% higher M/M in May. The FHFA Housing Price Index report also confirmed an increase of .7% in April. The S&P Case-Shiller Home Price Index report showed a 1.7% drop in April. The Conference Board’s Consumer Confidence Index report exhibited a significant mover up to 109.7 in June. The New home sales report showed a 12.2% M/M jump in May to a seasonally adjusted annual rate of 763k units & on a Y/Y basis, new home sales have moved up 20%. On Wednesday, the Weekly MBA Mortgage Applications Index report moved up to 3%. The May Advanced International Trade in Goods report came in at -$91.1B. The May Advanced Retail Inventories report came in at .8% & the May Advanced Wholesale Inventories report came in at -.1%. On Thursday, the third estimate for Q1 GDP report was upwardly revised to 2% as consumer spending came in better than expected, however the GDP Deflator was also moved slightly down to 4.1%. The Initial jobless claims report for the week ending June 24 dropped 26 kto 239k & the continuing jobless claims report for the week ending June 17 dropped 19k to 1.742M. The May Pending Home Sales report fell 2.7% M/M. On Friday, the Personal income report showed .4%M/M rise in May  & personal spending edged up .1%. The PCE Price Index report confirmed a move up by .1% & the Core-PCE Price Index rose .3%.  On a Y/Y basis, the PCE Price Index is up 3.8% but .5% lower than April. The core-PCE Price Index is  up 4.6% Y/Y a touch lower than in April. The final reading for the June University of Michigan Consumer Sentiment Index came in at 64.4 as folks seem to be feeling better about the inflation situation.  The June Chicago PMI came in higher at 41.5, but still well below the expansion cutoff. 

 The SPDR S&P Regional Banking ETF (KRE) rebounded by 3.16% over the last 5-days to close at $40.83 & the SPDR S&P Bank ETF (KBE) rose 3.42% over the last 5-days to close at $36. 

The CBOE Volatility Index (^VIX) closed at $13.59 & down 4.63% over the last 5-days.

As a result, the yield curve rose over the course of the week as the 2-yr note yield moved up 13bps to 4.88% & the 10-yr note yield moved up 8bps to 3.82%. The U.S. Dollar Index ticked higher to close the week at 103.92 up from 102.87 last Friday. 



As for the biotech sector, the Nasdaq Biotechnology ETF (IBB) closed at $126.96 -1.20% over the last 5-days and is now down 3.30% YTD, the NYSE ARCA Biotech Index (^BTK) closed at 5,225.24, -2.90% over the last 5-days and is now down 1.06% YTD, & the SPDR S&P Biotech ETF (XBI) pulled back to closed at $83.20, -2.26% over the last 5-days, & is now up .24% YTD. The 52-week range is is now $72.44-$95.18. Cathie Wood’s ARK Innovation ETF (ARKK) closed at $44.14, +4.75% over the last 5-days and is now up 41.29% YTD.  

The iShares U.S. Healthcare ETF (IYH) closed at $280.35, +.61% over the last 5-days and is now down 1.22% YTD.  

From the world of cryptocurrency, Bitcoin (BTC) moved to $30,507.07 & up .78% over the course of the last 5-days at the time of the completion of this message. 

Gold prices closed at $1,926, +$2/oz over the last 5-days. Silver prices closed at $22.85, -$.49/oz over the last 5-days. 


VP Watchlist Updates

On June 26, Lantern Pharma Inc. (NASDAQ: LTRN, $5.64, +9.51% over the last 5-days) an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs in place and with a mission to transform the cost, pace, and timeline of oncology drug discovery and development, announced the company has published new findings in Oncotarget demonstrating drug candidate LP-284’s in vitro and in vivo antitumor potency for multiple non-Hodgkin’s lymphomas (NHL), including mantle cell lymphoma (MCL) and double-hit lymphoma (DHL). The journal article titled “LP-284 Targets Non-Hodgkin’s Lymphoma and DNA Damage Repair Deficiency” further supports LP-284’s development for NHL and advancement towards a first-in-human Phase 1 trial, which is anticipated for the second half of 2023. Non-Hodgkin’s lymphomas (NHL) remain one of the leading causes of cancer deaths globally and have an estimated 500,000 new cases globally, with NHL being the leading hematological malignancy in the US. Despite advances for NHL using combination and targeted therapies, nearly 20% to 40% of patients with certain subtypes still relapse after treatment. In aggressive subtypes of NHL, like MCL, nearly all patients relapse from standard-of-care (SOC) therapies. READ MORE at this link.

Learn more about Lantern at their website https://www.lanternpharma.com


The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimates) unable to access affordable treatment. INVO Bioscience, Inc. (NASDAQ: INVO) offers the INVOcell solution which provides an advanced, effective and affordable infertility treatment to help increase access to care. INVO is commercially advancing INVOcell through the opening of INVO Centers, opportunistically now pursuing acquisitions of established fertility (IVF) clinics in the U.S., and continuing to offer the technology to existing fertility practices.  Shares INVO closed at $.2002, +21.33% over the last 5-days. The 52-wk range is $.15 – $1.65.

On June 27, INVO Bioscience, Inc. (NASDAQ: INVO,  $.2070), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture (“IVC”) procedure it enables, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to expand the labeling on the INVOcell device and its indication for use to provide for a 5-day incubation period. The data supporting the expanded 5-day incubation clearance demonstrated improved patient outcomes. Steve Shum, CEO of INVO stated, “This is a momentous day for INVO as the FDA has provided clearance for us to expand our labeling to cover a 5-day incubation period for INVOcell. This has been a multi-year effort to demonstrate INVOcell’s ability to improve patient outcomes using a longer incubation period, similar to conventional IVF results. We believe our ability to now communicate the improved success rates using INVOcell to patients and physicians will have a positive effect on the overall confidence and adoption of the technology going forward. The global fertility services market is a substantial, multi-billion-dollar industry and growing, with a significant underserved patient population. INVO’s commercial strategy remains focused on helping to expand affordable care to the underserved patients in need. The Company’s market approach includes the opening of dedicated “INVO Centers” offering INVOcell® and IVC procedure (three centers in North America now operational), the acquisition of existing profitable IVF clinics (signed binding agreements to acquire Wisconsin Fertility Institute), and the continued global distribution and sale of the INVOcell technology solution into existing fertility clinics. We believe the recent 510(k) clearance will help further support our overall commercial activities.”

On April 18, Maxim Group’s Analyst Jason McCarthy, Ph.D. issued a BUY rating on INVO Bioscience (INVO), a commercial-stage fertility company focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. His report is titled, “4Q Results and Outlook: Fertility Space Remains Active as INVO Expands Strategy with IVF Clinic Acquisition.” His 12-month Price Target is $3. 


  • Borqs Technologies, Inc. (Nasdaq: BRQS, $.166, -19.02% over the last 5-days), a global provider of 5G wireless solutions, Internet of Things (IoT) solutions, and innovative clean energy, recently provided the following updates on the Company.

On June 13, Borqs Technologies, Inc. (Nasdaq: BRQS), a global provider of 5G wireless and Internet of Things (IoT) solutions, announced its plans to further expand into artificial intelligence, leveraging its deep IoT expertise across industries.Beyond Borqs’ current product line for water and energy reservation for smart city applications, the Company plans to accelerate development of consumer-oriented devices and solutions with artificial intelligence capabilities. Artificial Intelligence of Things (AIoT) is defined as the combination of artificial intelligence (AI) technologies with the Internet of Things (IoT) to achieve more efficient IoT operations, improve human-machine interactions and enhance data management and analytics. Borqs further plans to commercialize products that are currently targeted to be applied in e-health, sports, education, and asset protection. According to a Global Market Insights Report dated May 2023, Artificial Intelligence of Things market size was valued at over USD 9 billion in 2022 and is anticipated to grow at a CAGR of 20% between 2023 and 2032.

  • On April 26, Borqs Technologies published its Letter to Shareholders Regarding the Divestment of Solar Subsidiary. “Dear Shareholders of Borqs Technologies, Inc. The purpose of this letter is to help clarify the proposed divestment of our company’s ownership in Holu Hou Energy, LLC (“HHE”) and the implications that this transaction may have to Borqs and our shareholders. Why the divestment? As we have stated in prior press releases, the Committee on Foreign Investment in the United States (“CFIUS”) has notified our company by a letter dated December 13, 2022, that CFIUS has identified risks to US national security arising as a result of Borqs’s investment in HHE. CFIUS advised us that the national security risks arising as a result of Borqs’s investment transaction with HHE relate to foreign proximity to U.S. military personnel and installations through HHE’s physical access to customers and their facilities, including at off-base military housing. CFIUS therefore required Borqs and HHE to enter into a National Security Agreement with CFIUS, pursuant to which Borqs must divest its interests in HHE. Proactive steps by Borqs. Read the balance here:” 
  • On April 20, Borqs announced that its subsidiary, Holu Hou Energy LLC (HHE), a provider of design-to-service solar plus energy storage systems, has signed a contract to install HHE’s HoluPower energy storage and solar photovoltaic (PV) systems on homes at Lendlease’s Island Palm Communities (IPC) in Honolulu, Hawaii. When completed, the project will be worth well into the nine figures in sales for HHE. Lendlease, a leading real estate and investment group that manages almost 8,000 homes for the U.S. Army on Oahu, is the purchaser of the electricity and the installations will come in the form of HHE’s EnergyCluster, where multiple residential units have their systems connected in an energy network or “cluster.” Excess solar generation from any unit’s system in the network that would normally be lost is directly shared in real time with other connected units that have load above solar generation. The benefit is that the optimized PV and energy storage systems can meet 75-80% or more of the overall residents’ energy needs while not exporting power to the utility grid. Lendlease and HHE began initial planning in 2021, which culminated in constructing a “pilot” project in May 2022. Since then, the pilot has been operating with outstanding results across six residential units. In a typical month, approximately a third of the total generated electricity is shared with other units in the “cluster” thereby solving issues related to vacancy and resident load variability, while proving out the superior value created through a clustered approach versus stand-alone systems. The savings realized by Island Palm Communities through deployment of HHE’s systems is being reinvested to enhance the housing and amenities Lendlease offers to military families on the installation. Additionally, residents now have resilient back-up power that can be utilized during grid outage events. These systems also take a load burden off the Oahu electric grid, which improves overall stability. Each residential unit will have approximately 10kW of PV and 25 kWh of energy storage, with six residences typically being connected in an HHE EnergyShare network. Construction is set to begin summer of 2023, with initial installations at the Aliamanu Military Reservation near Honolulu.



Shares of InMed Pharmaceuticals Inc. (INM), a leader in the research, development and manufacturing of rare cannabinoids, closed at $.9265, -.91% over the last 5-days.

  • On June 22, InMed announced safety and efficacy results from its Phase 2 clinical trial, called 755-201-EB (the “Phase 2 Trial”), for the treatment of symptoms related to EB. The purpose of the Phase 2 Trial was to evaluate the safety of INM-755 CBN cream, which consists of the control cream plus the active pharmaceutical ingredient CBN, and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with EB. All four subtypes of inherited EB, including EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome were accepted into the Phase 2 Trial. The Phase 2 Trial used a within-patient, double-blind design whereby matched index areas were randomized to INM-755 CBN cream or control cream. The Phase 2 Trial enrolled a total of 19 patients. Data from one patient were excluded from efficacy analyses due to a significant protocol deviation. Of the 18 remaining patients whose data were considered reliable for clinical review, 17 were treated for chronic non-wound itch and one patient was treated for wound-related itch. The remaining endpoints (pain, wound healing) could not be analyzed due to too few enrollees with such symptoms. Of the 18 participants assessed, chronic itch improved by a clinically meaningful amount in 12 patients (66.7%). InMed will pursue strategic partnership opportunities for INM-755 in epidermolysis bullosa (“EB”) and other itch-related skin conditions.
  • On June 1, InMed announced that results from a neurodegenerative disease study was presented in a scientific poster at the Canadian Neuroscience Meeting in Montreal from May 28-31, 2023. The InMed sponsored research, entitled “Cannabinoids modulate cytotoxicity and neuritogenesis in Amyloid-beta-treated neuronal cells”, demonstrated the ability of a specific rare cannabinoid (“pCBx”) in InMed’s 900 Series library of potential candidates that reduces amyloid toxicity and tau protein expression while enhancing neuronal cell growth and neuritogenesis markers in vitro, all considered to be important targets in the potential treatment of neurodegenerative diseases such as Alzheimer’s. The research was conducted in the laboratory of Dr. Ujendra Kumar and Dr. Rishi Somvanshi of the faculty of Pharmaceutical Sciences at the University of British Columbia. Studies have shown that cannabinoids, via their endocannabinoid receptors (CB1R and CB2R) that naturally occur in the human body and brain, reduce amyloid-beta (“Aβ”) toxicity, decrease p-tau protein expression and provide neurite outgrowth, thus improving neuronal viability and function. The results presented demonstrate the anti-apoptotic effects of pCBx and its role in neuritogenesis in the cells of neuronal origin and support the role of pCBx as a potential therapeutic intervention in neurodegenerative diseases.
  • On May 31, our sister organization, Tribe Public, hosted a Presentation & Q&A Webinar Event titled “InMed Pharmaceuticals (NASDAQ: INM) Addressing The Increasing Demand For Rare Cannabinoids.” The event was co-hosted by InMed Pharmaceutical’s (NASDAQ: INM) CEO Eric A. Adams, MIBS, & BayMedica’s Jerry P. Griffin, VP, Sales and Marketing. InMed Pharmaceuticals (NASDAQ: INM, $1.34, +6.35%) is a global leader in the development, manufacturing, and commercialization of rare cannabinoids, which is developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. i.e. Alzheimer’s Disease, Glaucoma, & a rare genetic skin disease, Epidermolysis Bullosa (EB). Together with its subsidiary, BayMedica LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. If you missed this event, then you may now watch the event video at the Tribe Public YouTube Channel by clicking here


Eric Adams recently stated, “In the last few months we have seen a noticeable increase in awareness, understanding and adoption of rare cannabinoids in the H&W sector, evidenced by leading companies expanding their product lines to include new formats and formulations using rare cannabinoids such as the non-psychoactive ingredient cannabichromene (“CBC”). We are encouraged by two consecutive periods of significant quarter over quarter revenue growth. We will continue to support growth in a fiscally prudent manner in this relatively nascent market, where product demand can be unpredictable. The combination of a pharmaceutical drug development pipeline, together with a revenue generating commercial operation that will be contributing to extending our cash runway makes InMed a unique company within the rare cannabinoid space.”


Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and radiation-induced lung injury, closed at $1.26, +41.57% over the last 5-days and 137.74% YTD.

On June 28, Atossa and Quantum Leap Healthcare Collaborative™ announced that six patients have been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the ongoing Phase 2 I-SPY 2 clinical trial. (Z)-endoxifen is being evaluated as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive (ER+) invasive breast cancer whose tumors are predicted to be sensitive to endocrine therapy but for whom chemotherapy is expected to provide little or no benefit.

On June 27, Atossa announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $10 million of its common stock through December 31, 2023.

On June 21, Atossa announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,680,036) directed to enterically encapsulated endoxifen compositions formulated as a suspension. These include all liquid suspension formulations suitable for oral administration and dispersible tablets, powders, granules, pellets or sprinkles for reconstitution, which are commonly used for pediatric administration. A suspension is a heterogeneous mixture. It differs from a solution, which is a homogeneous mixture, in that the particles in a solution are much smaller and are dissolved in a solvent, therefore staying mixed together. In a suspension, the particles are large, do not dissolve, and will separate. Advantages of suspension formulations may include ease of delivery of low soluble therapeutic agents, increased bioavailability of drug dosage, controlled drug delivery and resistance to degradation. Dr. Steven Quay, Atossa’s President and Chief Executive Officer, “Our new patent covering suspension formulations is important as we continue to learn more about the potential therapeutic role of endoxifen beyond breast cancer and mammographic breast density. Suspension formulations are particularly useful in pediatric applications where drugs are often dosed by weight and delivered via powders or sprinkles mixed with food and dispersible tablets, which are easier for children to ingest compared to tablets.”

On June 12, Atossa announced that the pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully enrolled. EVANGELINE is a randomized non-inferiority trial of Atossa’s patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. The PK run-in cohort consists of six patients, all of whom will be treated with (Z)-endoxifen at 40mg/day for four weeks. The goal of the PK run-in cohort is to determine if the 40mg dose delivers steady-state plasma concentrations (Css) between 500 – 1000 ng/mL, which are optimal to target PKCβ1 inhibition and enhance (Z)-endoxifen’s antitumor mechanism of action. Once the optimal dose of (Z)-endoxifen is determined, the Treatment Cohort will commence. Participants in the treatment cohort will receive neoadjuvant treatment for up to six months, followed by surgery. The study is expected to enroll approximately 175 patients at up to 25 sites across the United States.



Atossa’s CEO, Steven Quay, M.D., Ph.D., presented at a Tribe Public even titled “Atossa Therapeutics (NASDAQ: ATOS) Redefining Breast Cancer Prevention and Treatment” on Thursday, May 4, 2023. Dr. Quay provided an update on the clinical development of Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, which is currently being investigated in three separate Phase 2 studies. You may view the event at the following link at the Tribe Public YouTube Channel.

 

Recently, I c0-hosted a couple of our sister organization’s (Tribe Public) CEO Presentation and Q&A events that were held in Scottsdale and Peoria, AZ. The events were co-hosted by Travis Whitfill, MPH MPhil PhD(c), Cofounder and Chief Operating Officer of Azitra, Inc., a company that successfully priced their Initial Public Offering (IPO) on the Nasdaq with the ticker ‘AZTR’ recently on Friday, June 16, 2023 and closed trading today at $3.64. Mr. Whitfill provided a presentation about Azitra’s precision dermatology platform that is augmented by an artificial intelligenceand machine learning technology that analyzes, predicts, and helps screen our library of strains for drug like molecules. You can learn more about their company today at their website https://azitrainc.com.  Thanks again for those of you that joined this event and please note that I intend on hosting the Phoenix events on the last Thursday of each month going forward with a list of evolving companies that the Tribe is seeking to meet. If you want a direct invitation going forward for Scottsdale or other cities where the Tribe is hosting events, then please let me know.  Here’s a little more info Azitra’s CEO:

Travis Whitfill (pictured above) is a serial biotech entrepreneur. He is the is the cofounder and Chief Operating Officer at Azitra. His background began in molecular biology and biochemistry after receiving scientific training at the MD Anderson Cancer Center, Duke University, and Yale University. Previously, Travis was a Partner at Bios Partners, which is biotech-focused venture capital fund. He has sat on the board of several portfolio companies, including 410 Medical, Immusoft Corporation, IN8bio (NASDAQ: INAB) and SIRPant Immunotherapeutics. He also is an Assistant Professor Adjunct in the Departments of Pediatrics and Emergency Medicine at Yale University. Mr. Whitfill has led numerous grant-funded projects, holds nearly a dozen patents, and has co-authored over 50 publications.

He was on Forbes’ 30 under 30 list (healthcare) in 2018. Mr. Whitfill received degrees from Yale University (MPH), University College London (MPhil), Dallas Baptist University (BS), and is finishing a PhD from University College London in innovation and economics.

 


Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive iPSC-derived Natural Killer (iNK) cell and Flex-NK™ bispecific antibody platforms. The company is developing three types of iNK cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia’s proprietary Flex-NK™ technology. These two technology platforms are being used to develop treatment for patients with solid tumors such as HCC and glioblastoma as well as hematological malignancies such as refractory multiple myeloma. Headquartered in Aventura, FL., Cytovia has research and development laboratories in Natick, MA. The company’s own R&D work is augmented through scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, the National Cancer Institute, and the University of California San Francisco (UCSF). Cytovia has a partnership with CytoLynx Therapeutics focused on research and development, manufacturing, and commercialization activities in Greater China.

On May 17, Cytovia Therapeutics R&D Team Presented Poster at ASGCT 2023 on GPC3-Targeted TALEN® Gene-Edited CAR-iNK Cell.

On Dec. 9, 2022, Cytovia announced new preclinical data for its CD38-targeted Flex-NK™ bispecific antibody at the American Society of Hematology’s 64th Annual Meeting (ASH 2022) taking place in New Orleans, LA, and virtually December 10-13th, 2022. “We’re delighted to see further progress on our CD38-targeted Flex-NK™ bispecific antibody program, with a pre-clinical package that supports clinical evaluation in 2023,” commented Cytovia CEO Dr. Daniel Teper. “The data presented at ASH suggests that CYT-338, our CD38-targeted Flex-NK™ Bispecific Antibody, has a differentiated profile compared to daratumumab, the leading CD38-targeted monoclonal antibody and that CYT-338 may have the ability to overcome NK cell exhaustion and dysfunction.”  Cytovia believes that by redirecting and activating NK cells to kill myeloma cells, bispecific antibodies have the potential to offer new options for patients not responding to first lines of treatment.”



Shares of ADT Inc. (ADT), the most trusted brand in smart home and small business security, closed at $6.03, +2.90% over the last 5-days. On May 2, ADT reported results for the first quarter of 2023 highlighting strong year-over-year growth in revenue; CSB and Commercial up 7% and 15%, respectively, versus prior year period, maintained record high customer retention and new record high recurring monthly revenue balance, improved capital efficiency with record revenue payback, & continued deleveraging with over $400 million debt reduction expected in 2023.


Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates and let’s find ways to crush it again this year!

Investing & Inspiration

  1. “Science may never come up with a better office communication system than the coffee break.” – Earl Wilson
  2. “If everyone is moving forward together, then success takes care of itself.” – Henry Ford
  3. “Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind us.”– Samuel Smiles
  4. “Patriotism is supporting your country all the time, and your government when it deserves it.” – Mark Twain
  5. “What would life be if we had no courage to attempt anything?” – Vincent Van Gogh
  6. “The biggest risk is not taking any risk… In a world that is changing really quickly, the only strategy that is guaranteed to fail is not taking risks.” – Mark Zuckerberg
  7. “Our lives improve only when we take chances – and the first and most difficult risk we can take is to be honest with ourselves.” – Walter Anderson
  8. “Action is the foundational key to all success.” – Pablo Picasso
  9. “Success is never final, failure is never fatal. It’s courage that counts.” – John Wooden
  10. “Innovation distinguishes between a leader and a follower.” – Steve Jobs
  11. “All the art of living lies in a fine mingling of letting go and holding on.” – Havelock Ellis
  12. “The size of your success is measured by the strength of your desire; the size of your dream; and how you handle disappointment along the way.” – Robert Kiyosaki
  13. “O, wind, if winter comes, can spring be far behind?” – Percy Bysshe Shelley
  14. “Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk
  15. “Be true to your work, your word, and your friend.” – John Boyle O’Reilly
  16. “Believe in yourself! Have faith in your abilities! Without a humble but reasonable confidence in your own powers you cannot be successful or happy.” – Norman Vincent Peale
  17. “Surprise is the greatest gift which life can grant us.” – Boris Pasternak
  18. “Logic will get you from A to B. Imagination will take you everywhere.” – Albert Einstein
  19. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  20. “Do exactly what you would do if you felt most secure.” – Meister Eckhart
  21. “Life lived for tomorrow will always be just a day away from being realized.” – Leo Buscaglia
  22. “Wisdom is oftentimes nearer when we stoop than when we soar.” – Wordsworth
  23. “Take chances, make mistakes. That’s how you grow. Pain nourishes your courage. You have to fail in order to practice being brave.” – Mary Tyler Moore
  24. “A single twig breaks, but the bundle of twigs is strong.” – Tecumseh
  25. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  26. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  27. “The limits of the possible can only be defined by going beyond them into the impossible.” – Arthur C. Clarke
  28. “Be faithful in small things because it is in them that your strength lies.” – Mother Teresa
  29. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
  30. “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
  31. “No man was ever wise by chance.” – Lucius Annaeus Seneca
  32. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  33. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
  34. “It does not matter how slowly you go as long as you do not stop.” – Confucius

  35. “I want to put a ding in the universe.” – Steve Jobs

  36. “Research is creating new knowledge.” – Neil Armstrong

  37. “The reward for work well done is the opportunity to do more.” – Jonas Salk
  38. “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
  39. “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey
  40. “Success seems to be largely a matter of hanging on after others have let go.” – William Feather

  41. “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger
  42. “More business is lost every year through neglect than through any other cause.” – Rose Kennedy

  43. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes

  44. “A person who won’t read has no advantage over one who can’t read.” – Mark Twain
  45. “The best way out is always through.” – Robert Frost

  46. “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi
  47. “Without labor nothing prospers.” – Sophocles

  48. “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein
  49. “This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt

  50. “The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller

  51. “He who is brave is free.” – Lucius Annaeus Seneca
  52. “When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk

  53. “I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin

  54. “Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll

  55. “He who knows that enough is enough will always have enough.” – Lao Tzu

  56. “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall
  57. “In order to carry a positive action we must develop here a positive vision.” – Dalai Lama

  58. “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
  59. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  60. “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
  61. “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
  62. “You must do the things you think you cannot do.”- Eleanor Roosevelt
  63. “Success is dependent on effort.” – Sophocles
  64. “Nobody who ever gave his best regretted it.” – George Halas
  65. “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
  66. “And when I breathed, my breath was lightning.” – Black Elk
  67. “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
  68. “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
  69. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  70. “We are an impossibility in an impossible universe.” – Ray Bradbury
  71. “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
  72. “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
  73. Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
  74. “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
  75. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
  76. Surprise is the greatest gift which life can grant us.” –  Boris Pasternak
  77. “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran 
  78. “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
  79. “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
  80. “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” –  Colin Powell
  81. “There is more to life than increasing its speed.” – Mahatma Gandhi
  82. “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
  83. “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
  84. “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
  85. “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
  86. “Life is too short for long-term grudges.” – Elon Musk
  87. There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
  88. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
  89. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
  90. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
  91. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
  92. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
  93. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
  94. “Let there be work, bread, water and salt for all.” – Nelson Mandela
  95. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
  96. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  97. “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
  98. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  99. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
  100. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
  101. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
  102. “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
  103. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
  104. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
  105. “Delete the negative; accentuate the positive!” – Donna Karan
  106. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
  107. “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
  108. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
  109. “Everything has beauty, but not everyone sees it.” – Confucius
  110. A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
  111. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
  112. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
  113. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  114. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  115. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
  116. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  117. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
  118. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  119. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
  120. “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
  121. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
  122. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
  123. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
  124. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  125. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
  126. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
  127. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
  128. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  129. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  130. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  131. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  132. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  133. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese 
  134. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  135. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  136. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  137. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  138. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  139. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  140. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  141. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  142. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  143. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  144. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch 
  145. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  146. “The secret of getting ahead is getting started.” – Mark Twain
  147. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe

Videos



Post View Count : 501